Standing Up for Seniors

May 5th, 2014 - RetireSafe collected 200* surveys at a senior expo asking questions that affect older Americans.

1)    Does your Social Security check keep up with inflation?
       Yes    30              No   168
2)    Do you wish Obamacare had never happened and our healthcare had remained as it was?
       Yes    150            No     47
3)    Would you like your doctor alerted if your pharmacist made any changes or substitutions to your prescription?
       Yes    185           No    15

* Some questions were not answered

Standing Up for America’s Seniors Award

RetireSafe continues to recognize those members of Congress who are not afraid to stand up for America’s seniors. Read more about the award.

RetireSafe, a sponsor at the Florida Conference on Aging, presented a seminar on what's happening in Washington from two different perspectives. Read more...

RetireSafe traveled to Louisville, KY to educate seniors about policy solutions concerning aging in place (AIP) and elder abuse.  Read more...

RetireSafe was a sponsor of the National Association of Nutrition and Aging Services Programs conference in San Diego, California.  Our focus was highlighting the importance of nutrition in allowing older Americans to age in place.



President's Message

Safety First: Commonsense Rules for New Medicine

President Thair Phillips

Americans are blessed to have exciting, relatively new, medicines called “biologics” that can treat, cure or help manage devastating diseases like diabetes, cancer, HIV/AIDS, multiple sclerosis (MS), autoimmune diseases like rheumatoid arthritis, as well as heart attacks and strokes. For older Americans, these are truly “miracle” drugs that extend and enhance our lives. These are also expensive drugs, developed after years of costly research and many, many failures on the long road to success. As we all thankfully benefit from cutting-edge biologics, we also search for ways to reduce the costs.

One of the most promising ways to provide greater access to these powerful biologics and achieve some savings is the development of “biosimilars,” drugs that are similar to the original or “reference” biologics. Please note that they are “similar,” not exact copies, and not generic as are some “small-molecule” drugs that we are familiar with today. These are not the simple compound pills that we are used to, but rather complex compounds made from living organisms. Biosimilars can never be exactly the same drugs as the original biologics, which is especially important considering the possible adverse reaction each patient’s immune system may have to the biosimilar. That’s why patient advocates, and the U.S. Food and Drug Administration (FDA), are rightly focused on the rules under which biosimilars can be developed, manufactured, sold and used. As with the original drugs they seek to be similar to, biosimilars must be safe for patient use.


As the FDA moves toward issuing final guidance on biosimilars it is important that they consider the following commonsense safety rules that will continue to keep our medicines safe and effective:

  • Like the reference drugs they would copy, all biosimilar drugs should face extensive clinical trials to determine their safety and effectiveness.
  • If the original biologic treats multiple ailments, the follow-on biosimilar should be required to pass clinical trials on each and every one of those therapeutic applications. Nothing should be assumed with our lives at stake.
  • All biosimilars should have unique names to eliminate any and all confusion for patients, physicians, pharmacists, and regulators. This would also facilitate the extensive tracking system that must be in place to mitigate problems and track any adverse reactions after each biosimilar hits the market.
  • At the pharmacy, both patients and physicians should be fully informed before any drug switch involving biosimilars is made. That is simply commonsense policy to protect patients from what could be serious adverse reactions, and there should be no debate on this critical safeguard.

Patient safety must come first if we are to reap the benefits of these new lifesaving medicines.
Please take the survey on biosimilars at the bottom right of this home page.  Make your voice heard!  We will publish the results of the survey in the next few weeks.

More thoughts from President Phillips...


RetireSafe News
Current News

 Will Obamacare leave us with unsafe medicine? Click HERE to find out how this could happen and take our survey.




Issues  |  Advocacy  |  Newsroom  |  About Us   |  Login
Copyright 2014 - All Rights Reserved   |  Privacy Statement  |  Terms Of Use  |  Website Created by PS Software